161 related articles for article (PubMed ID: 28039657)
1. Self-Reported Questionnaire Detects Family History of Cancer in a Pancreatic Cancer Screening Program.
Lucas AL; Tarlecki A; Van Beck K; Lipton C; RoyChoudhury A; Levinson E; Kumar S; Chung WK; Frucht H; Genkinger JM
J Genet Couns; 2017 Aug; 26(4):806-813. PubMed ID: 28039657
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts.
Lucas AL; Frado LE; Hwang C; Kumar S; Khanna LG; Levinson EJ; Chabot JA; Chung WK; Frucht H
Cancer; 2014 Jul; 120(13):1960-7. PubMed ID: 24737347
[TBL] [Abstract][Full Text] [Related]
3. Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening.
Cremin C; Lee MK; Hong Q; Hoeschen C; Mackenzie A; Dixon K; McCullum M; Nuk J; Kalloger S; Karasinska J; Scudamore C; Kim PTW; Donnellan F; Lam ECS; Lim HJ; Neben CL; Stedden W; Zhou AY; Schaeffer DF; Sun S; Renouf DJ; Schrader KA
Cancer Med; 2020 Jun; 9(11):4004-4013. PubMed ID: 32255556
[TBL] [Abstract][Full Text] [Related]
4. Cancer history: A predictor of IPMN subtype and dysplastic status?
Carr RA; Kiel BA; Roch AM; Ceppa EP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM
Am J Surg; 2018 Mar; 215(3):522-525. PubMed ID: 29174163
[TBL] [Abstract][Full Text] [Related]
5. PanGen-Fam: Spanish registry of hereditary pancreatic cancer.
Mocci E; Guillen-Ponce C; Earl J; Marquez M; Solera J; Salazar-López MT; Calcedo-Arnáiz C; Vázquez-Sequeiros E; Montans J; Muñoz-Beltrán M; Vicente-Bártulos A; González-Gordaliza C; Sanjuanbenito A; Guerrero C; Mendía E; Lisa E; Lobo E; Martínez JC; Real FX; Malats N; Carrato A
Eur J Cancer; 2015 Sep; 51(14):1911-7. PubMed ID: 26212471
[TBL] [Abstract][Full Text] [Related]
6. High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer.
Bannon SA; Montiel MF; Goldstein JB; Dong W; Mork ME; Borras E; Hasanov M; Varadhachary GR; Maitra A; Katz MH; Feng L; Futreal A; Fogelman DR; Vilar E; McAllister F
Cancer Prev Res (Phila); 2018 Nov; 11(11):679-686. PubMed ID: 30274973
[No Abstract] [Full Text] [Related]
7. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
[TBL] [Abstract][Full Text] [Related]
8. Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study.
Kimura H; Ohtsuka T; Matsunaga T; Watanabe Y; Tamura K; Ideno N; Aso T; Miyazaki T; Osoegawa T; Aishima S; Miyasaka Y; Ueda J; Ushijima Y; Igarashi H; Ito T; Takahata S; Oda Y; Mizumoto K; Tanaka M
Pancreas; 2015 Oct; 44(7):1148-54. PubMed ID: 26284536
[TBL] [Abstract][Full Text] [Related]
9. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers.
Vasen H; Ibrahim I; Ponce CG; Slater EP; Matthäi E; Carrato A; Earl J; Robbers K; van Mil AM; Potjer T; Bonsing BA; de Vos Tot Nederveen Cappel WH; Bergman W; Wasser M; Morreau H; Klöppel G; Schicker C; Steinkamp M; Figiel J; Esposito I; Mocci E; Vazquez-Sequeiros E; Sanjuanbenito A; Muñoz-Beltran M; Montans J; Langer P; Fendrich V; Bartsch DK
J Clin Oncol; 2016 Jun; 34(17):2010-9. PubMed ID: 27114589
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
11. Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program.
Joergensen MT; Gerdes AM; Sorensen J; Schaffalitzky de Muckadell O; Mortensen MB
Pancreatology; 2016; 16(4):584-92. PubMed ID: 27090585
[TBL] [Abstract][Full Text] [Related]
12. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance.
Canto MI; Almario JA; Schulick RD; Yeo CJ; Klein A; Blackford A; Shin EJ; Sanyal A; Yenokyan G; Lennon AM; Kamel IR; Fishman EK; Wolfgang C; Weiss M; Hruban RH; Goggins M
Gastroenterology; 2018 Sep; 155(3):740-751.e2. PubMed ID: 29803839
[TBL] [Abstract][Full Text] [Related]
13. Missed pancreatic ductal adenocarcinoma: Assessment of early imaging findings on prediagnostic magnetic resonance imaging.
Jang KM; Kim SH; Kim YK; Song KD; Lee SJ; Choi D
Eur J Radiol; 2015 Aug; 84(8):1473-1479. PubMed ID: 26032128
[TBL] [Abstract][Full Text] [Related]
14. Current Approaches to Pancreatic Cancer Screening.
Chhoda A; Lu L; Clerkin BM; Risch H; Farrell JJ
Am J Pathol; 2019 Jan; 189(1):22-35. PubMed ID: 30558719
[TBL] [Abstract][Full Text] [Related]
15. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.
Gold DV; Gaedcke J; Ghadimi BM; Goggins M; Hruban RH; Liu M; Newsome G; Goldenberg DM
Cancer; 2013 Feb; 119(3):522-8. PubMed ID: 22898932
[TBL] [Abstract][Full Text] [Related]
16. Interobserver agreement and accuracy of preoperative endoscopic ultrasound-guided biopsy for histological grading of pancreatic cancer.
Larghi A; Correale L; Ricci R; Abdulkader I; Monges G; Iglesias-Garcia J; Giovannini M; Attili F; Vitale G; Hassan C; Costamagna G; Rindi G
Endoscopy; 2015 Apr; 47(4):308-14. PubMed ID: 25521572
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
Levink IJM; Klatte DCF; Hanna-Sawires RG; Vreeker GCM; Ibrahim IS; van der Burgt YEM; Overbeek KA; Koopmann BDM; Cahen DL; Fuhler GM; Wuhrer M; Bonsing BA; Tollenaar RAEM; Vleggaar FP; Vasen HFA; van Leerdam ME; Bruno MJ; Mesker WE
Pancreatology; 2022 May; 22(4):497-506. PubMed ID: 35414481
[TBL] [Abstract][Full Text] [Related]
18. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
[TBL] [Abstract][Full Text] [Related]
19. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
Parikh DA; Durbin-Johnson B; Urayama S
J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
[TBL] [Abstract][Full Text] [Related]
20. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
